sponsored
PatientsVille.com Logo

PatientsVille

Cymevan Medical Research Studies

Up-to-date List of Cymevan Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cymevan Medical Research Studies

Rank Status Study
1 Recruiting Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
Conditions: Cytomegalovirus Anterior Segment Infection;   Anterior Uveitis;   Endotheliitis
Intervention: Drug: Ganciclovir
Outcome Measures: Median concentration of ganciclovir in anterior chamber and ocular surface;   Correlation of intracameral concentration of virgan with the corneal thickness
2 Unknown  A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis
Conditions: Keratoconjunctivitis Due to Adenovirus;   Viral Shedding
Interventions: Drug: Zirgan;   Drug: genteal gel
Outcome Measures: Time to Viral Eradication;   Development of sub-epithelial infiltrates;   Degree of Bulbar conjunctival Injection;   Second eye involvment
3 Recruiting Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
Condition: Infection in Solid Organ Transplant Recipients
Interventions: Drug: Ganciclovir/ Valganciclovir according to SPC;   Drug: Ganciclovir/ Valganciclovir according to PK model
Outcome Measures: Area under the concentration time curve (AUC)of ganciclovir in steady state;   CMV viral load measured by quantitative polymerase chain reaction (PCR);   T-cell immune response against CMV infection measured by Enzyme-linked immunosorbent spot (ELISPOT)
4 Recruiting Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure
Conditions: Acute Lung Injury;   Acute Respiratory Distress Syndrome;   Respiratory Failure
Interventions: Drug: IV Ganciclovir;   Drug: Placebo
Outcome Measures: Serum IL-6 level;   Incidence of CMV reactivation at 28 days (blood, throat);   Additional cytokine levels;   Clinical outcomes;   Length of stay;   CMV disease;   Safety;   Functional assessment
5 Unknown  Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
Conditions: Conjunctivitis;   Adenovirus.
Interventions: Drug: Ophthalmic gel (placebo);   Drug: Ganciclovir
Outcome Measures: time to regression of the ocular symptomatology;   Development of sub-epithelial infiltrates;   Degree of Bulbar conjunctival Injection;   Involvement of the second eye;   Patient Dairy - intensity of ocular pain
6 Recruiting Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection
Condition: Cytomegalovirus Infections
Intervention:
Outcome Measures: Plasma pharmacokinetics parameters for ganciclovir Area Under the Curve at 12 hours (AUC12);   Plasma pharmacokinetics parameters for ganciclovir, including maximum serum concentration (Cmax), half-life (T1/2), CL, and Vd;   Correlation of ganciclovir plasma concentrations with CMV whole blood viral load;   Correlation of ganciclovir plasma concentrations with clearance of CMV in urine;   Correlation of ganciclovir plasma concentrations with neutropenia;   Detection of resistance to ganciclovir
7 Recruiting PTH - Preemptive Treatment for Herpesviridae
Condition: Viral Pneumonia
Interventions: Drug: Aciclovir;   Drug: Ganciclovir;   Drug: Placebo
Outcome Measures: Ventilator-free days at Day 60;   Day 60 mortality;   ICU mortality;   Hospital mortality;   Duration of mechanical ventilation in survivors;   Duration of ICU stay;   Duration of hospital stay;   Incidence of ventilator-associated pneumonia;   Incidence of bacteremia;   SOFA score;   Acute renal failure related to aciclovir or its placebo;   Leucopenia related to ganciclovir or its placebo;   Time to oropharyngeal negativation of HSV PCR;   Time to blood negativation of CMV PCR;   Incidence of herpetic bronchopneumonia;   Incidence of active CMV infection
8 Unknown  Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients
Condition: Liver Transplantation
Intervention: Drug: oral Valganciclovir vs oral Ganciclovir
Outcome Measure:
9 Unknown  Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis
Condition: Cytomegalovirus Endotheliitis
Intervention:
Outcome Measure: clinical courses before and after topical ganciclovir in patients with CMV endotheliitis
10 Recruiting Cytomegalovirus Control in Critical Care
Condition: Critical Illness
Interventions: Drug: Valaciclovir/Aciclovir;   Drug: Valganciclovir/Ganciclovir
Outcome Measures: Time to reactivation of cytomegalovirus (CMV) polymerase chain reaction (PCR) (defined as above the lower limit of sample assay).;   Time to reactivation above the lower limit of assay detection of CMV PCR in urine, throat swab and non-directed bronchiolar lavage (NDBL). NDBL whilst trachea is intubated only.;   Time to >1000 CMV copies in blood, urine, throat swab and NDBL (NDBL whilst intubated);   Time to >10000 CMV copies in blood, urine, throat swab and NDBL (NDBL whilst intubated);   CMV PCR in blood, urine, throat swab and NDBL (NDBL whilst intubated);   Markers of inflammation;   Clinical Outcomes;   Number of Serious Adverse events;   Time to neutropenia (count <1.0x10-9/L);   Time to thrombocytopenia (platelet <50x10-9/L);   Use of G-CSF or termination of study drug;   Number of platelet transfusions received;   Time to renal insufficiency (CrCl <60ml/min, <30ml/min, need for renal support)
11 Unknown  Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
Condition: Cytomegalovirus
Interventions: Drug: ganciclovir treatment or monitoring of viral load.;   Other: Monitor or treat with ganciclovir
Outcome Measures: Group A # with low level of CMV who develop a viral load > 3000 copies/ml & Group B # who develop a 2nd episode of a viral load above 3000 copies/ml after therapy stopped.;   To define the duration of antiviral therapy needed to treat CMV viraemia. To record the rate of increase in viral load prior to starting preemptive therapy & to correlate viral loads with CMV specific immune function.
12 Unknown  Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis
Condition: Anterior Uveitis
Intervention:
Outcome Measures: Anterior chamber inflammation;   probability of relapse-free
13 Recruiting Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Cytomegalovirus Disease
Interventions: Drug: Certican (everolimus) + valganciclovir;   Drug: Valganciclovir
Outcome Measures: relative changes in CMV-load (copies/mL), as determined by qCMV-PCR from whole blood throughout the observational period;   CMV-load (copies/mL) after 1-8 weeks, in months 3, 4, 6 and 12; Time (in weeks) until the CMV-load reaches ≤600 copies/mL
14 Unknown  T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
Conditions: Graft Versus Host Disease;   Nonneoplastic Condition
Interventions: Biological: adoptive immunotherapy;   Biological: alemtuzumab;   Biological: in vitro-treated peripheral blood lymphocyte therapy;   Drug: foscarnet sodium;   Drug: ganciclovir;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: infection prophylaxis and management;   Procedure: peripheral blood stem cell transplantation;   Procedure: standard follow-up care;   Radiation: radiation therapy
Outcome Measures: CMV reactivation in the first year after ASCT measured by quantitative PCR;   CMV-specific T-cell reconstitution by detection of circulating T-cell responses to CMV in the first year after ASCT;   Time to CMV reactivation;   Use of antiviral therapy;   Incidence of secondary CMV reactivation and CMV disease;   Incidence of acute and chronic graft-versus-host disease
15 Not yet recruiting Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss
Conditions: Congenital Cytomegalovirus;   Hearing Loss
Interventions: Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution;   Drug: Placebo
Outcome Measures: The proportion of children whose change in total ear hearing assessments (improved + no change versus other);   The proportion of children who have change in best ear hearing assessments [improved + no change (normal to normal) versus other; and worse versus other];   The quantitative log reduction in viruria;   The proportion of children who have viremia;   The quantitative log reduction in viremia;   The proportion of children who have CMV detected in saliva by PCR;   The quantitative log reduction in CMV viral load in saliva;   The proportion of children whose sensorineural hearing improves or remains unchanged from baseline when measured;   The correlation of change in viral load with change in total ear and best ear hearing;   The change in total ear hearing assessments (improved versus other).;   The proportion of children who have CMV viruria detected by PCR;   The incidence of unanticipated medically attended visits;   Incidence of adverse events which lead to permanent discontinuation of valganciclovir therapy or have an unresolved outcome
16 Recruiting An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls
Condition: Cytomegalovirus Infections, Transplantation
Intervention:
Outcome Measures: Change of sperm density at end of treatment;   Percentage of DNA fragmentation changes;   Semen: volume, sperm density/motility/morphology;   Hormone/biomarker levels (FSH/LH/testosterone/prolactin/inhibin B)
17 Recruiting Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT
Condition: Cytomegalovirus Infections
Intervention: Biological: CMV Specific T Cell donor lymphocyte infusion
Outcome Measures: Safety of CMV Specific T cell infusion following Stem Cell Transplant;   Efficacy of CMV-specific T cell infusion in terms of response, progression free survival, and overall survival;   Evaluate the recovery of immune function post engraftment with this regimen.
18 Recruiting Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
Condition: Cytomegalovirus Infection
Interventions: Biological: Adoptive Cellular Therapy;   Drug: Best available antiviral drug therapy
Outcome Measure: CMV reactivations
19 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
Outcome Measures: Hearing assessment;   Child development;   Viral load
20 Not yet recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Kidney Transplantation;   Epstein-Barr Virus Infections/Complications;   Cytomegalovirus Infections/Complications
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
Outcome Measures: Change in incidence and magnitude of CMV and EBV viremia in kidney transplant;   Change in number of dose-limiting side effects in kidney transplant recipients receiving valA vs. valG.;   To identify the presence and quantity of EBV and CMV in renal tissue biopsies from kidney transplant recipients.

These studies may lead to new treatments and are adding insight into Cymevan etiology and treatment.

A major focus of Cymevan research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Cymevan